JP2022502358A5 - - Google Patents

Info

Publication number
JP2022502358A5
JP2022502358A5 JP2021514549A JP2021514549A JP2022502358A5 JP 2022502358 A5 JP2022502358 A5 JP 2022502358A5 JP 2021514549 A JP2021514549 A JP 2021514549A JP 2021514549 A JP2021514549 A JP 2021514549A JP 2022502358 A5 JP2022502358 A5 JP 2022502358A5
Authority
JP
Japan
Application number
JP2021514549A
Other languages
Japanese (ja)
Other versions
JP7476174B2 (ja
JP2022502358A (ja
JPWO2020058360A5 (https=
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/EP2019/075065 external-priority patent/WO2020058360A1/en
Publication of JP2022502358A publication Critical patent/JP2022502358A/ja
Publication of JP2022502358A5 publication Critical patent/JP2022502358A5/ja
Publication of JPWO2020058360A5 publication Critical patent/JPWO2020058360A5/ja
Priority to JP2024067065A priority Critical patent/JP2024102112A/ja
Application granted granted Critical
Publication of JP7476174B2 publication Critical patent/JP7476174B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

JP2021514549A 2018-09-18 2019-09-18 がんに対するa*01拘束性ペプチドおよびペプチド組み合わせによる免疫療法 Active JP7476174B2 (ja)

Priority Applications (1)

Application Number Priority Date Filing Date Title
JP2024067065A JP2024102112A (ja) 2018-09-18 2024-04-17 がんに対するa*01拘束性ペプチドおよびペプチド組み合わせによる免疫療法

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US201862732863P 2018-09-18 2018-09-18
US62/732,863 2018-09-18
DE102018122900.3 2018-09-18
DE102018122900 2018-09-18
PCT/EP2019/075065 WO2020058360A1 (en) 2018-09-18 2019-09-18 Immunotherapy with a*01 restricted peptides and combination of peptides against cancers and related methods

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2024067065A Division JP2024102112A (ja) 2018-09-18 2024-04-17 がんに対するa*01拘束性ペプチドおよびペプチド組み合わせによる免疫療法

Publications (4)

Publication Number Publication Date
JP2022502358A JP2022502358A (ja) 2022-01-11
JP2022502358A5 true JP2022502358A5 (https=) 2023-06-16
JPWO2020058360A5 JPWO2020058360A5 (https=) 2023-06-16
JP7476174B2 JP7476174B2 (ja) 2024-04-30

Family

ID=68062920

Family Applications (2)

Application Number Title Priority Date Filing Date
JP2021514549A Active JP7476174B2 (ja) 2018-09-18 2019-09-18 がんに対するa*01拘束性ペプチドおよびペプチド組み合わせによる免疫療法
JP2024067065A Pending JP2024102112A (ja) 2018-09-18 2024-04-17 がんに対するa*01拘束性ペプチドおよびペプチド組み合わせによる免疫療法

Family Applications After (1)

Application Number Title Priority Date Filing Date
JP2024067065A Pending JP2024102112A (ja) 2018-09-18 2024-04-17 がんに対するa*01拘束性ペプチドおよびペプチド組み合わせによる免疫療法

Country Status (19)

Country Link
US (10) US10954281B2 (https=)
EP (1) EP3852787A1 (https=)
JP (2) JP7476174B2 (https=)
KR (1) KR20210063320A (https=)
CN (1) CN113164569A (https=)
AU (1) AU2019342860A1 (https=)
BR (1) BR112021003511A2 (https=)
CA (1) CA3108582A1 (https=)
CL (3) CL2021000653A1 (https=)
CO (1) CO2021003404A2 (https=)
CR (1) CR20210141A (https=)
IL (2) IL309715A (https=)
MA (1) MA53644A (https=)
MX (1) MX2021003089A (https=)
PE (1) PE20211643A1 (https=)
PH (1) PH12021550581A1 (https=)
SG (1) SG11202101926TA (https=)
TW (1) TW202024121A (https=)
WO (1) WO2020058360A1 (https=)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
BR112019020959A2 (pt) 2017-04-10 2020-05-05 Immatics Biotechnologies Gmbh peptídeos e combinações dos mesmos para uso na imunoterapia contra câncer
US11427614B2 (en) 2017-04-10 2022-08-30 Immatics Biotechnologies Gmbh Peptides and combination thereof for use in the immunotherapy against cancers
WO2021188743A2 (en) * 2020-03-20 2021-09-23 Neo7Logix, Llc Precision-based immuno-molecular augmentation (pbima) computerized system, method and therapeutic vaccine
US12525329B2 (en) * 2020-03-20 2026-01-13 Neo7Bioscience, Inc. Precision-based immuno-molecular augmentation (PBIMA) computerized system, method, and therapeutic vaccine
AU2021256477A1 (en) * 2020-04-14 2022-11-10 Université de Montréal Novel tumor-specific antigens for acute myeloid leukemia (AML) and uses thereof
CN115843747B (zh) * 2022-12-02 2024-08-20 吉林大学 一种Lama3基因点突变的小鼠模型及其构建方法

Family Cites Families (45)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4440859A (en) 1977-05-27 1984-04-03 The Regents Of The University Of California Method for producing recombinant bacterial plasmids containing the coding sequences of higher organisms
US4704362A (en) 1977-11-08 1987-11-03 Genentech, Inc. Recombinant cloning vehicle microbial polypeptide expression
IL59007A (en) 1978-12-22 1983-11-30 Biogen Nv Recombinant dna molecules coding for polypeptides displaying hepatitis b virus antigenicity,method of their production and compositions containing the same
US4530901A (en) 1980-01-08 1985-07-23 Biogen N.V. Recombinant DNA molecules and their use in producing human interferon-like polypeptides
US4342566A (en) 1980-02-22 1982-08-03 Scripps Clinic & Research Foundation Solid phase anti-C3 assay for detection of immune complexes
US4678751A (en) 1981-09-25 1987-07-07 Genentech, Inc. Hybrid human leukocyte interferons
US4766075A (en) 1982-07-14 1988-08-23 Genentech, Inc. Human tissue plasminogen activator
US4582800A (en) 1982-07-12 1986-04-15 Hoffmann-La Roche Inc. Novel vectors and method for controlling interferon expression
US4816567A (en) 1983-04-08 1989-03-28 Genentech, Inc. Recombinant immunoglobin preparations
US4757006A (en) 1983-10-28 1988-07-12 Genetics Institute, Inc. Human factor VIII:C gene and recombinant methods for production
US4677063A (en) 1985-05-02 1987-06-30 Cetus Corporation Human tumor necrosis factor
US4810648A (en) 1986-01-08 1989-03-07 Rhone Poulenc Agrochimie Haloarylnitrile degrading gene, its use, and cells containing the gene
US4897445A (en) 1986-06-27 1990-01-30 The Administrators Of The Tulane Educational Fund Method for synthesizing a peptide containing a non-peptide bond
AU6852594A (en) 1993-06-03 1995-01-03 Therapeutic Antibodies Inc. Production of antibody fragments
AUPM322393A0 (en) 1993-12-24 1994-01-27 Austin Research Institute, The Mucin carbohydrate compounds and their use in immunotherapy
ES2203782T3 (es) 1996-01-17 2004-04-16 Imperial College Innovations Limited Inmunoterapia que utiliza linfocitos t citotoxicos (ctl).
US5849589A (en) 1996-03-11 1998-12-15 Duke University Culturing monocytes with IL-4, TNF-α and GM-CSF TO induce differentiation to dendric cells
US6406705B1 (en) 1997-03-10 2002-06-18 University Of Iowa Research Foundation Use of nucleic acids containing unmethylated CpG dinucleotide as an adjuvant
DE60142475D1 (de) 2000-03-27 2010-08-12 Technion Res And Dev Of Founda Einkettige haupthistokompatibilitätskomplexe der klasse i (mhc-i), kodierende konstrukte und methoden ihrer erzeugung
US20040191260A1 (en) 2003-03-26 2004-09-30 Technion Research & Development Foundation Ltd. Compositions capable of specifically binding particular human antigen presenting molecule/pathogen-derived antigen complexes and uses thereof
EP2322228B1 (en) 2000-06-05 2018-01-10 Altor BioScience Corporation T cell receptor fusion proteins and conjugates and methods of use thereof
US6992176B2 (en) 2002-02-13 2006-01-31 Technion Research & Development Foundation Ltd. Antibody having a T-cell receptor-like specificity, yet higher affinity, and the use of same in the detection and treatment of cancer, viral infection and autoimmune disease
AU2003216341A1 (en) 2002-02-20 2003-09-09 Dyax Corporation Mhc-peptide complex binding ligands
AU2003271904B2 (en) 2002-10-09 2009-03-05 Adaptimmune Limited Single chain recombinant T cell receptors
DE60327795D1 (de) 2002-11-09 2009-07-09 Immunocore Ltd T zell rezeptor "display"
GB0304068D0 (en) 2003-02-22 2003-03-26 Avidex Ltd Substances
ES2341802T3 (es) 2005-09-05 2010-06-28 Immatics Biotechnologies Gmbh Peptidos asociados a tumores unidos promiscuamente a moleculas del antigeno de leucocito humano (hla) de clase ii.
US20090263574A1 (en) 2008-04-21 2009-10-22 Quinn Daniel E Method of restoring an article
WO2010037395A2 (en) 2008-10-01 2010-04-08 Dako Denmark A/S Mhc multimers in cancer vaccines and immune monitoring
US9840695B2 (en) 2009-04-28 2017-12-12 Agriculture Victoria Services Pty Ltd Plant technology
GB201006360D0 (en) 2010-04-16 2010-06-02 Immatics Biotechnologies Gmbh Method for differentially quantifying naturally processed HLA-restricted peptides for cancer, autoimmune and infectious diseases immunotherapy development
US20140170168A1 (en) 2010-10-26 2014-06-19 Yoram Reiter Antibodies which bind soluble t-cell receptor ligands
WO2013057586A1 (en) 2011-10-19 2013-04-25 Oslo Universitetssykehus Hf Compositions and methods for producing soluble t - cell receptors
US12540318B2 (en) 2012-11-08 2026-02-03 Roche Diagnostics Operations, Inc. Nucleic acids encoding chimeric polypeptides for library screening
EP2808392A1 (en) 2013-05-28 2014-12-03 Rheinische Friedrich-Wilhelms-Universität Bonn Aptamers and use of the aptamers in the diagnosis and treatment of cancer
GB201319446D0 (en) 2013-11-04 2013-12-18 Immatics Biotechnologies Gmbh Personalized immunotherapy against several neuronal and brain tumors
GB201505305D0 (en) * 2015-03-27 2015-05-13 Immatics Biotechnologies Gmbh Novel Peptides and combination of peptides for use in immunotherapy against various tumors
CA2988388C (en) 2015-04-23 2022-11-22 Nantomics, Llc Cancer neoepitopes
GB201513921D0 (en) 2015-08-05 2015-09-23 Immatics Biotechnologies Gmbh Novel peptides and combination of peptides for use in immunotherapy against prostate cancer and other cancers
GB201520559D0 (en) 2015-11-23 2016-01-06 Immunocore Ltd & Adaptimmune Ltd Peptides
GB201521894D0 (en) * 2015-12-11 2016-01-27 Immatics Biotechnologies Gmbh Novel peptides and combination of peptides for use in immunotherapy against various cancers
EP3446119A1 (en) 2016-04-18 2019-02-27 The Broad Institute Inc. Improved hla epitope prediction
GB201609193D0 (en) * 2016-05-25 2016-07-06 Immatics Biotechnologies Gmbh Novel peptides, combination of peptides as targets for use in immunotherapy against gallbladder cancer and cholangiocarcinoma and other cancers
US11175289B2 (en) * 2016-11-16 2021-11-16 Lei Han Application of TRPM8 protein, related peptide fragment and their antibodies
RU2020103379A (ru) 2017-07-04 2021-08-04 Куревак Аг Новые молекулы нуклеиновых кислот

Similar Documents

Publication Publication Date Title
BR112021017339A2 (https=)
BR112021018450A2 (https=)
BR112021017637A2 (https=)
BR112021017892A2 (https=)
BR112021017782A2 (https=)
BR112021016821A2 (https=)
BR112021017939A2 (https=)
BR112021017738A2 (https=)
BR112021016996A2 (https=)
BR112021017728A2 (https=)
AU2020104490A5 (https=)
BR112021013944A2 (https=)
JP2022502358A5 (https=)
BR112021018452A2 (https=)
BR112021017703A2 (https=)
BR112021018102A2 (https=)
BR112021017732A2 (https=)
BR112021017234A2 (https=)
BR112021017355A2 (https=)
BR112021018168A2 (https=)
BR112021018093A2 (https=)
BR112021017173A2 (https=)
BR112021017083A2 (https=)
BR112021015080A2 (https=)
BR112021018250A2 (https=)